PHARMACOLOGICAL AND TOXICOLOGICAL PROPERTIES OF 2‐METHYL‐3‐PIPERIDINOPYRAZINE, A NEW ANTIDEPRESSANT *

In the search for potential antidepressant agents chemically unrelated to hydrazine, tryptamine, phenethylamine, iminodibenzyl, or N-alkylpiperidinol derivatives, a new group of compoundst possessing a substituted pyrazine ring has been discovered. It is reasoned that the introduction of new chemical entities exhibiting empirical pharmacological correlates of clinical antidepressant action might contribute to the chemotherapy of mental disorders. The new compounds might have a qualitatively different spectrum of activity and help to eliminate undesirable effects inherent to known agents. The representative member of the pyrazine series is 2-methyl-3-piperidinopyrazine . HCl (W3207A). The originality of W3207A as a new medicinal-chemical entity is illustrated by the following formulae:

[1]  P. Feldman.  COMPARISON OF EFFECT OF 2‐METHYL‐3‐PIPERIDINOPYRAZINE ON TARGET SYMPTOMS OF ANERGIC SCHIZOPHRENICS * , 1963, Annals of the New York Academy of Sciences.

[2]  D. F. Morgan,et al.  INHIBITION OF MONOAMINE OXIDASE BY 2‐METHYL‐3‐PIPERIDINOPYRAZINE , 1963 .

[3]  E. Dunlop.  ANTIDEPRESSANT EFFECTS OF MAO INHIBITORS * , 1963 .

[4]  H. Maling,et al.  Neurologic, neuropathologic, and neurochemical effects of prolonged administration of phenylisopropylhydrazine (JB 516), phenylisobutylhydrazine (JB 835), and other monoamine oxidase inhibitors. , 1962, The Journal of pharmacology and experimental therapeutics.

[5]  I. W. Hillyard,et al.  The cardiovascular and extravascular smooth muscle actions of chlorphentermine hydrochloride (p-chloro-alpha, alpha-dimethylphenethylamine)-A new anorexigenic agent. , 1962, The Journal of pharmacology and experimental therapeutics.

[6]  L. Valzelli,et al.  EFFECT OF IMIPRAMINE, AMITRIPTYLINE AND THEIR MONOMETHYL DERIVATIVES ON RESERPINE ACTIVITY , 1962, The Journal of pharmacy and pharmacology.

[7]  S. P'an,et al.  Anticonvulsant Effect of Nialamide and Diphenylhydantoin.∗ ‡ , 1961, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[8]  Vernier Vg.  The pharmacology of antidepressant agents. , 1961 .

[9]  A. Horita.  Some pharmacological aspects of monoamine oxidase regulators. , 1961, Journal of Neuropsychiatry.

[10]  D. H. Tedeschi,et al.  In vivo Monoamine Oxidase Inhibition Measured by Potentiation of Tryptamine Convulsions in Rats , 1960, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[11]  R. Bagdon,et al.  PHARMACOLOGY OF IPRONIAZID AND OTHER AMINE OXIDASE INHIBITORS , 1959, Annals of the New York Academy of Sciences.

[12]  B. Brodie,et al.  ANTICONVULSANT PROPERTIES OF MONOAMINE OXIDASE INHIBITORS , 1959, Annals of the New York Academy of Sciences.

[13]  J. Biel,et al.  STRUCTURE AND ACTIVITY RELATIONSHIPS OF MONOAMINE OXIDASE INHIBITORS , 1959, Annals of the New York Academy of Sciences.

[14]  W. Burkard,et al.  IN VITRO AND IN VIVO INHIBITION OF AMINE OXIDASES , 1959 .

[15]  C. C. Scott,et al.  Modifications of the pharmacology of reserpine and serotonin by iproniazid. , 1957, The Journal of pharmacology and experimental therapeutics.

[16]  F. Wilcoxon,et al.  A simplified method of evaluating dose-effect experiments. , 1948, The Journal of pharmacology and experimental therapeutics.

[17]  V. G. Vernier.  The pharmacology of antidepressant agents. , 1961, Diseases of the nervous system.